Navigation Links
For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
Date:7/20/2009

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that most surveyed clinicians identify a need for additional therapies from the GLP-1 analogue and DPP-IV inhibitor drug classes for the treatment of type 2 diabetes. In particular, surveyed physicians identify a greater need for new GLP-1 analogues, owing to the shortcomings of the current GLP-1 analogue, Amylin/Eli Lilly's Byetta. Surveyed physicians indicate that Byetta's shortcomings include frequent injections and high levels of nausea associated with treatment. Additionally, clinicians indicate that the shortcomings of Merck's DPP-IV inhibitor Januvia include less glucose-lowering compared to metformin and a lack of long-term safety data.

The new Physician & Payer Forum report entitled A Clinician and Payer Perspective on Changing Dynamics in the Diabetes Market: Is There Room for New GLP-1 Analogues or DPP-IV Inhibitors? finds that 89 percent of surveyed endocrinologists and 77 percent of surveyed primary care physicians (PCPs) indicate there is a need for additional GLP-1 analogue therapies. The report also finds that 71 percent of endocrinologists and 74 percent of PCPs indicate there is a need for additional DPP-IV therapies.

Similarly, 75 percent of surveyed managed care organizations' (MCOs) pharmacy directors indicate that additional agents are needed within the GLP-1 analogue class, and 70 percent indicate a need for additional agents from the DPP-IV inhibitor class. Forty-five percent of MCOs indicate that a novel antidiabetic agent's glucose-lowering efficacy compared with that of existing drugs carries the most weight in their decision whether to include the novel drug in their formulary and to what tier it should be assigned.

"Surveyed clinicians indicate that although the feature of Ja
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. -Contrave(R) Obesity Research Phase 3 Program Meets Co-Primary and Key Secondary Endpoints; Exceeds FDA Efficacy Benchmark for Obesity Treatments-
2. Lumenis UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
3. Innovative Prostate Cancer Treatment Known as Sonablate(R) HIFU Now Available at Third Site in India
4. Addiction Treatment Will Help Make Health Reform Affordable, New Analysis Shows
5. Mylan Receives FDA Approval for Generic Version of Thyroid Deficiency Treatment Cytomel(R)
6. Cancer Patients Benefit From Speed, Accuracy of RapidArc Radiotherapy Treatments
7. Beijing Cancer Hospital Becomes First Hospital in Mainland China to Introduce Fast and Precise RapidArc Radiotherapy Cancer Treatments
8. New Outpatient Treatment for Heartburn-Related Problem Stops Esophageal Cancer Before It Starts
9. Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer
10. New Treatments for Alzheimers on the Horizon
11. Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... What’s next for 14 year old Sriram ... National Spelling Bee? Sririam will visit Philadelphia on Friday, ... Wills Eye Hospital.     , The teen from Painted Post, ... day. , Wills Eye Ophthalmologist-in-Chief, Dr. Julia Haller will ... visual diagnostic testing. He will also tour historic ...
(Date:8/27/2014)... Amy Norton HealthDay ... People who take part in clinical trials of new heart ... heart patient, a new study confirms. Experts said the ... the American Medical Association , aren,t surprising -- but they ... are enrolling a more select patient population that is not ...
(Date:8/27/2014)... August 27, 2014 Tejal K. Gandhi, MD, ... (NPSF) and the NPSF Lucian Leape Institute, is among ... August 25 issue of Modern Healthcare magazine. Also on the ... Andrew Sussman, MD, MBA; NPSF Lucian Leape Institute members ... who is a member of both the Institute and the ...
(Date:8/27/2014)... Silver Spring and Germantown, Md., and Denver (PRWEB) August ... healthcare real estate developer , has broken ground ... on the new Holy Cross Health hospital campus in ... of Bethesda, Md. Germantown is the third most populous ... medical office building on the Holy Cross Germantown Hospital ...
(Date:8/27/2014)... a parent wants to deal with, but it,s unfortunately ... old. , Skin that turns yellow can be a ... adequately eliminating the chemical bilirubin. But that discoloration is ... can harm a baby. , University of Washington engineers ... for jaundice in newborns and can deliver results to ...
Breaking Medicine News(10 mins):Health News:Scripps National Spelling Bee Co-Champion and Aspiring Ophthalmologist Coming to Wills Eye Hospital in Philadelphia 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 2Health News:Heart Studies Don't Reflect Real-World Patients, Study Finds 3Health News:NPSF President Among 100 Most Influential in Health Care 2Health News:NPSF President Among 100 Most Influential in Health Care 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 2Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 3Health News:NexCore Breaks Ground on Medical Office Building on Holy Cross Health Campus in Germantown, Maryland 4Health News:New smartphone app can detect newborn jaundice in minutes 2Health News:New smartphone app can detect newborn jaundice in minutes 3
... , , , , ... Outstanding Debt to be Reduced by Approximately $54.8 Million , ... , Company to Book Approximately $8.2 Million Estimated ... by Approximately $45.4 Million , , , , ...
... ... been among the first to use NeoPlas Innovation,s new protocol. , ... Nashville, Tenn. (Vocus) June 16, 2009 -- With an ... his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and ...
... as Unwarranted, Withdraws Two Cold Remedy Nasal Products Citing Commitment ... June 16 Matrixx Initiatives, Inc. (Nasdaq: MTXX ... from the U.S. Food and Drug Administration about two of ... Gel and Zicam Cold Remedy Swabs. The warning letter cited ...
... CHICAGO, June 16 David O. Barbe, M.D., a ... the Board of Trustees of the American Medical Association. , ... , , "I am honored to be elected to the ... representing physicians as the AMA and the nation focus on health-care ...
... change" says new leader of American medicine , , ... cardiologist from Bryan, Texas, was inaugurated today as the 164th ... and most influential physician organization. , , (Logo: ... In his inaugural address as AMA president, Dr. Rohack spoke ...
... Food and Drug Administration (FDA) today advised consumers to stop ... cold remedies under the Zicam(R) brand because the use of ... of smell (a condition called anosmia ). ... zinc ingredient, The Quigley Corporation (Nasdaq: QGLY ), ...
Cached Medicine News:Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 2Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 3Health News:Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding 4Health News:Inoperable Colon Cancer Responds to New Treatment 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:AMA Inaugurates J. James Rohack as President 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 2Health News:Cold-EEZE(R) Lozenges not Affected by FDA Advisory for Zicam(R) Intra-Nasal Products 3
(Date:8/27/2014)... , Aug. 27, 2014 Ambit Biosciences (Nasdaq: ... development of drugs targeting unmet needs in oncology, autoimmune and ... 2014 Health Care Conference to be held at The New ... on September 3-4, 2014. Alan Fuhrman ... and its lead drug candidate, quizartinib, at 1:10 p.m. ET ...
(Date:8/27/2014)... , Aug. 27, 2014 IRIDEX Corporation (NASDAQ: ... James H. Mackaness is scheduled to make an investor ... at 2:55 p.m. Eastern Time on Wednesday, September 3, in ... of the investor presentation will be available in the Investors ... About IRIDEX IRIDEX Corporation was founded ...
(Date:8/27/2014)... 27, 2014 Sinovac Biotech Ltd. (NASDAQ: SVA ... , today announced the results of the Company,s 2014 Annual ... Beijing , PRC. The required quorum, a majority ... The Company,s shareholders approved the following proposals:  , ... , Simon Anderson , Kenneth Lee and ...
Breaking Medicine Technology:Ambit Announces Participation At Baird 2014 Health Care Conference 2Sinovac Announces Results of 2014 Annual General Meeting of Shareholders 2
... Misonix, Inc. (NASDAQ: MSON ), a ... innovative therapeutic ultrasonic products worldwide for wound debridement, ... other surgical and medical applications, has entered into ... Solutions Australasia Pty. Ltd., based in Newport, Victoria, ...
... Aug. 12, 2011 Southern Research Institute today announced ... named Vice President of the Drug Discovery Division. Dr. ... research and target identification and lead discovery ... diseases and neurological diseases and disorders. ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Australia and New Zealand 2Misonix Announces New Distribution Agreement for Australia and New Zealand 3Southern Research Names Mark Suto Vice President of Drug Discovery 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: